Media ReleasesImmutep

View All Immutep News


Immutep Announces Progress Towards Clinical Development of IMP761 - a LAG-3 Agonist Antibody

SYDNEY, AUSTRALIA – Immutep Limited (ASX:IMM; NASDAQ:IMMP) (“Immutep”, the “Company”), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, announces that it will commence cell line development and the associated manufacturing steps for IMP761, an immunosuppressive agonist antibody to LAG-3.

This signals the advancement of IMP761 towards Good Manufacturing Practice (GMP) manufacturing and clinical development for the treatment of autoimmune diseases by Immutep and follows new and encouraging preclinical results that demonstrate the immunosuppressive activity of IMP761 in vivo.


For further information please download PDF attached:
Download this document